News
After Decades Without Progress in Glioblastoma, Diakonos Stirs Up Interest in Dendritic Cell Vaccine
The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback